Scientific strategy for biotech, spinout, and investor teams
Founder-led strategy for life-science teams making high-stakes decisions in translational science, metabolic disease, competitive positioning, KOL synthesis, and scientific narrative.
Who we help
Biotech founders
Preparing for fundraising, platform positioning, or strategic inflection points where the science needs to hold up under scrutiny.
Academic spinouts
Translating discoveries into investable stories, credible development plans, and clear scientific narratives.
Investors & BD teams
Needing independent scientific diligence, landscape analysis, or KOL-informed perspective on early-stage opportunities.
Medtech-adjacent teams
Working at the intersection of metabolic disease, clinical workflow, digital health, and physician adoption.
What we deliver
Strategic Scientific Memo
Hypothesis-driven analysis for board, investor, or internal decision-making — the signature deliverable, supported by diligence, landscape, KOL, narrative, spinout, and retainer services.
A focused edge in metabolic disease strategy
Especially suited for questions in diabetes, obesity, incretin biology, islet biology, beta-cell function, glucagon biology, and translational metabolic disease — where scientific nuance, clinical momentum, and competitive strategy increasingly overlap.
Explore metabolic strategy →Founder-led scientific strategy
Valdez BioStrategy is led by Ivan A. Valdez, PhD — a Harvard-trained biomedical scientist and former healthcare strategy consultant with deep experience in diabetes and metabolic disease research, translational science, and competitive landscape analysis.
Meet the founder →Specialized expertise, engaged by scope
Valdez BioStrategy is founder-led by Ivan A. Valdez, PhD. When a scoped question calls for complementary expertise, specialized advisors may contribute perspective across clinical strategy, commercialization, neuroscience, cancer biology, and biomedical science.
See the advisory bench →Have a scientific strategy question?
For confidential biotech, spinout, investor, or strategic diligence inquiries, start with a brief scoping conversation.
Request a confidential scoping call